Moderna reports Q2 GAAP EPS of -$1.97 and revenue of $145M, exceeding analyst expectations while maintaining full-year outlook.
Moderna posted a Q2 GAAP loss per share of $1.97, beating estimates by $0.09, as revenue rose 2.1% year-over-year to $145M, surpassing forecasts by $41.12M.
The company’s cash position stood at $6.9 billion as of June 30, 2026, down from $7.5 billion at the end of the prior quarter. Despite the decline, Moderna reaffirmed its full-year guidance, signaling confidence in its financial trajectory.
Shares showed limited immediate reaction as investors digested the mixed results, with earnings outperforming but cash reserves contracting.